Gives FDA an ironclad rationale for awarding AA to SRPT when it didn't to GSK
Gives GSK a reason to negotiate ex-US partnership with SRPT, if it can't use its patent due to safety issues
Gives strong floor value to SRPT even if it doesn't get AA; i.e. it won't disappear due to GSK competition but will become drug of choice upon approval.
Gives more companies including GSK a reason to attempt a buyout.
If everybody can get eteplirsen except those in the UK, what do you think the UK families will do? Sarepta can pay a royalty but it won't be much, if anything, because UK families will leave the UK for treatment. Their sons are more important than their country of residence.